Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% of cases of colorectal cancer have a genetic basis and about 15% of these patients have a disease-causing (pathogenic) inherited (germline) variant in a cancer susceptibility gene. Most individuals carrying a pathogenic germline variant are unaware of their cancer risk and may not meet guidelines for genetic testing. Identifying pathogenic germline variants or hereditary cancer syndromes in cancer patients has important implications for their at-risk relatives who may not know that they are at high risk for cancer. The burden of communicating this risk to first-degree relatives often falls on the patients, who may lack sufficient knowledge to correctly share and explain their genetic test results. Receiving provider-mediated communication of genetic testing results may be more effective at communicating genetic risk to first-degree relatives than the usual practice of proband-mediated communication.
PRIMARY OBJECTIVES:
I. To compare the proportion of first-degree relatives (FDRs) of probands with Lynch Syndrome who undergo germline testing in the provider-mediated arm (Arm B) versus the proband-mediated (Arm A) at 6 months.
II. To compare the proportion of FDRs of proband with a non-Lynch pathogenic germline variant who undergo germline testing in the provider-mediated arm (Arm B) versus the proband-mediated arm (Arm A) at 6 months.
SECONDARY OBJECTIVE:
I. To compare the proportion of FDRs with a pathogenic germline variant (PGV) who underwent disease prevention efforts at 12 months between the provider-mediated arm (Arm B) and the proband-mediated cascade testing arm (Arm A).
EXPLORATORY OBJECTIVES:
I. To assess differences in percentages of cascade genetic testing within the following proband subgroups: race/ethnicity (non-Hispanic whites; other race/ethnicities), sex (females; males), age (>= 50; < 50), tumor location (colon; rectal), tumor stage (stage I-II; stage III-IV), geographic location (urban; rural), and receipt of medical care in an academic versus (vs.) community setting.
III. To determine the prevalence and spectrum of pathogenic germline variants in cancer susceptibility genes by analysis of results of upfront germline testing in a multi-site cancer cooperative group study population with newly diagnosed CRC.
IV. Assess the pattern of accrual of demographic patient subgroups including racial/ethnic minority and rural individuals at the initial 50% of accrual enrolled and at the end of the trial.
V. To compare disease-free survival (DFS) of the proband at 3 years between the direct-contact arm (Arm B) and the proband-directed cascade testing arm (Arm A).
V. To evaluate the completion rate of a Social Determinants of Health questionnaire with patient directed questions .
OUTLINE:
STEP 1: Patients (probands) undergo collection of blood samples and genetic testing on study.
STEP 2: Probands with pathogenic or likely pathogenic germline variants and their FDRs are randomized to 1 of 2 arms.
ARM A: FDRs receive proband-mediated communication about the proband's genetic testing results.
ARM B: FDRs receive provider-mediated communication about the proband's genetic testing results.
Probands are followed for up to 3 years and FDRs are followed for up to 1 year
Inclusion Criteria:
STEP 1 PROBANDS: Age >= 18 years
STEP 1 PROBANDS: Patients with a newly diagnosed (within 3 months of registration), primary colorectal adenocarcinoma, stage I to IV
STEP 1 PROBANDS: No patients with stage 0 or in-situ colorectal cancer
STEP 1 PROBANDS: Patients who have had prior malignancies are eligible, including non-invasive cancers
STEP 1 PROBANDS: Patients with synchronous second malignancies are eligible
STEP 1 PROBANDS: Have not received germline testing in the 2 years prior to enrollment or known hereditary colon cancer syndromes
STEP 1 PROBANDS: Patients must have at least 2 living FDRs who meet the eligibility criteria, with whom the patient is willing to share their cancer diagnosis
STEP 1 PROBANDS: In order to complete the mandatory patient-completed measures and view the video and receive genetic education and counseling, participants must be able to speak and read English or Spanish
STEP 1 PROBANDS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members
* No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
STEP 2 PROBANDS: Probands positive for a pathogenic germline variant (PGV) in a cancer susceptibility gene
FDRs: Age >= 18 years
FDRs: Have not previously received germline genetic testing or known hereditary colon cancer syndromes
FDRs: FDRs must reside within the United States, as genetic testing from LabCorp is only available to United States (U.S.) residents
FDRs: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish
Exclusion Criteria:
-
rwills@bsd.uchicago.edu773-702-9814
Anchorage, Alaska 98508, United States
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
Arroyo Grande, California 93420, United States
Burbank, California 91505, United States
San Luis Obispo, California 93401, United States
Lexington, Kentucky 40509, United States
Mount Sterling, Kentucky 40353, United States
Westminster, Maryland 21157, United States
Ann Arbor, Michigan 48106, United States
Brighton, Michigan 48114, United States
Canton, Michigan 48188, United States
Chelsea, Michigan 48118, United States
East China Township, Michigan 48054, United States
kforman1@hfhs.org313-343-3166
Grosse Pointe Woods, Michigan 48236, United States
Grosse Pointe Woods, Michigan 48236, United States
Ypsilanti, Michigan 48197, United States
Crosslake, Minnesota 56442, United States
Detroit Lakes, Minnesota 56501, United States
International Falls, Minnesota 56649, United States
Maple Grove, Minnesota 55369, United States
Pequot Lakes, Minnesota 56472, United States
Pine River, Minnesota 56474, United States
Goldsboro, North Carolina 27534, United States
Jacksonville, North Carolina 28546, United States
Fargo, North Dakota 58103, United States
Cincinnati, Ohio 45219, United States
West Chester, Ohio 45069, United States
Silverdale, Washington 98383, United States
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
AKPAMC.OncologyResearchSupport@providence.org907-212-6871
Veronica.Stevenson@foundationhealth.org907-458-3043
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
800-378-9373
Research@CARTI.com501-906-4199
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
Najee.Boucher@providence.org818-847-4793
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@commonspirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
707-521-3830
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
707-521-3830
707-521-3830
707-967-3698
209-461-5257
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
eileen.georgi@holy-cross.com
stephanie.couch@stjoeshealth.org734-712-3671
eslinget@slhs.org208-381-2774
stephanie.couch@stjoeshealth.org734-712-3671
mccinfo@mtcancer.org406-969-6060
eslinget@slhs.org208-381-2774
stephanie.couch@stjoeshealth.org734-712-3671
eslinget@slhs.org208-381-2774
mccinfo@mtcancer.org406-969-6060
eslinget@slhs.org208-381-2774
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
eslinget@slhs.org208-381-2774
618-463-5623
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
clinical.research@sih.net618-457-5200
clinical.research@sih.net618-985-3333
andersonj@illinoiscancercare.com309-243-3605
morganthaler.jodi@mhsil.com217-876-4762
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
815-285-7800
Research@carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
Research@carle.com800-446-5532
gayla.hall@ssmhealth.com618-899-1894
Research@Carle.com800-446-5532
Research@Carle.com800-446-5532
morganthaler.jodi@mhsil.com217-876-4762
morganthaler.jodi@mhsil.com217-876-4762
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
andersonj@illinoiscancercare.com309-243-3605
815-664-4141
andersonj@illinoiscancercare.com309-243-3605
815-227-2633
217-545-7929
800-444-7541
pallante.beth@mhsil.com217-528-7541
Research@carle.com800-446-5532
andersonj@illinoiscancercare.com309-243-3605
clinical.trials@daytonncorp.org937-528-2900
aroland@kccop.org913-948-5588
aroland@kccop.org913-948-5588
888-446-3729
785-270-4939
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
410-601-9083
cancerinstitute@lifebridgehealth.org410-601-4673
Jeanmarie.downing@umm.edu410-337-4569
410-871-6400
CVResearch@mymichigan.org989-631-2469
CVResearch@mymichigan.org989-631-2469
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
Kkeenan1@hfhs.org313-343-3166
wstrong@ghci.org810-762-8038
wstrong@ghci.org810-762-8038
wstrong@ghci.org810-762-8038
wstrong@ghci.org810-762-8038
CVResearch@mymichigan.org989-631-2469
kforman1@hfhs.org313-343-3166
karen.forman@ascension.org313-343-3166
kforman1@hfhs.org313-343-3166
harsha.trivedi@umhsparrow.org517-364-3712
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
kforman1@hfhs.org313-343-3166
kforman1@hfhs.org313-343-3166
CVResearch@mymichigan.org989-631-2469
CVResearch@mymichigan.org989-631-2469
Emily.Crofts@trinity-health.org248-858-6215
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
kforman1@hfhs.org313-343-3166
kforman1@hfhs.org313-343-3166
kforman1@hfhs.org313-343-3166
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
MCRCwebsitecontactform@stjoeshealth.org734-712-7251
CancerTrials@EssentiaHealth.org218-786-3308
218-828-2880
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
218-692-1010
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
218-365-7900
CancerTrials@EssentiaHealth.org218-786-3308
218-786-3308
218-283-9431
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1572
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
218-485-4481
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
218-568-4416
218-587-4416
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
218-894-7870
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
mmcorc@healthpartners.com952-993-1517
888-446-3729
aroland@kccop.org913-948-5588
417-269-4520
888-446-3729
sfmc@sfmc.net573-334-2230
314-996-5569
LJCrockett@freemanhealth.com417-347-4030
esmeralda.carrillo@mercy.net417-556-3074
clinicaltrials@lakeregional.com573-302-2768
573-458-6379
research@phelpshealth.org573-458-7504
Trisha.England2@mymlc.com816-271-7937
314-996-5569
417-269-4520
417-269-4520
888-446-3729
Danielle.Werle@mercy.net314-525-6042
314-996-5569
314-251-7066
314-996-5569
636-390-1600
mccinfo@mtcancer.org406-969-6060
research@billingsclinic.org800-996-2663
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
protocols@AllianceNCTN.org773-702-9171
mccinfo@mtcancer.org406-969-6060
mccinfo@mtcancer.org406-969-6060
amy.hanneman@providence.org406-327-3118
mccinfo@mtcancer.org406-969-6060
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
Renown-CRD@renown.org775-982-5050
jfields@cancersmoc.com919-587-9084
tammy.cozad@caromonthealth.org704-834-2810
jfields@cancersmoc.com919-587-9084
jfields@cancersmoc.com910-587-9084
704-671-7031
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
330-363-1250
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
ClinicalReserachDept@aultman.com330-363-7274
cancer@uchealth.com513-584-7698
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@daytonncorp.org937-528-2900
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
clinical.trials@daytonncorp.org937-528-2900
cancer@uchealth.com513-584-7698
clinical.trials@daytonncorp.org937-528-2900
405-752-3402
mccinfo@mtcancer.org406-969-6060
nosall@stcharleshealthcare.org541-706-2909
CanRsrchStudies@providence.org503-215-2614
cherie.cox@bayareahospital.org541-269-8392
canrsrchstudies@provdience.org503-215-1979
CanRsrchStudies@providence.org503-215-2614
mccinfo@mtcancer.org406-969-6060
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
CanRsrchStudies@providence.org503-215-2614
541-706-2909
Morgan_M.Horton@lvhn.org610-402-9543
Morgan_M.Horton@lvhn.org610-402-9543
Morgan_M.Horton@lvhn.org610-402-9543
Morgan_M.Horton@lvhn.org610-402-9543
research@monument.health605-755-2370
deidre.dillon@providence.org360-412-8958
achapman1@peacehealth.org360-788-8223
deidre.dillon@providence.org360-412-8958
PCRC-NCORP@Swedish.org206-215-2343
marilyn.birchman@providence.org425-261-3529
PCRC-NCORP@Swedish.org206-215-2343
research@kadlecmed.org509-783-4637
deidre.dillon@providence.org360-412-8958
kmakin-bond@peacehealth.org360-514-2016
rcccclinicalresearch@skagitvalleyhospital.org360-814-2182
PCRC-NCORP@Swedish.org206-215-3086
PCRC-NCORP@Swedish.org206-215-3086
PCRC-NCORP@Swedish.org206-215-2343
achapman1@peacehealth.org360-788-8239
ResearchInstituteInquiries@CommonSpirit.org720-874-1881
research@ccnw.net509-228-1680
research@ccnw.net509-228-1680
research@ccnw.net509-228-1680
kmakin-bond@peacehealth.org360-514-3940
Cheryl.Dodd@providence.org509-897-5993
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
CancerTrials@EssentiaHealth.org218-786-3308
218-568-4416
mmcorc@healthpartners.com952-993-1517
CancerTrials@EssentiaHealth.org218-786-3308
701-364-6272
protocols@AllianceNCTN.org773-702-9171
research@billingsclinic.org800-996-2663
787-395-7085
787-780-2865
787-621-4397
787-274-3387
ctsucontact@westat.com888-823-5923
info@PRoncology.com787-919-7919
787-763-1296